Clinical Trials Browser

Unknown × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Phase 1/2 Unknown

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT03695744 2023-07-10

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03641456 2023-06-18

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Phase 2 Unknown

Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Phase 2 Unknown

Recurrence, Neoplasms, Plasma Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00389701 2014-01-10

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02027220 2014-01-06

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Phase 2 Unknown

Neoplasms, Plasma Cell

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00028886 2013-09-17

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00438841 2009-03-13

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell